267 related articles for article (PubMed ID: 34136385)
1. Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
Stagno A; Vari S; Annovazzi A; Anelli V; Russillo M; Cognetti F; Ferraresi V
Front Oncol; 2021; 11():645008. PubMed ID: 34136385
[TBL] [Abstract][Full Text] [Related]
2. Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy.
Myrdal CN; Sundararajan S
Case Rep Oncol Med; 2020; 2020():4392562. PubMed ID: 32670650
[TBL] [Abstract][Full Text] [Related]
3. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
4. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma.
Amann VC; Hoffmann D; Mangana J; Dummer R; Goldinger SM
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1638-1640. PubMed ID: 28401596
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
7. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
8. A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma.
Fedele D; Moroso S; Turoldo A; Bazzocchi G; Conforti C; Zalaudek I; Guglielmi A
Case Rep Oncol; 2024; 17(1):161-168. PubMed ID: 38288458
[TBL] [Abstract][Full Text] [Related]
9. BRAF
Finke C; Mohr P
Adv Ther; 2024 May; ():. PubMed ID: 38806993
[TBL] [Abstract][Full Text] [Related]
10. Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.
Swofford BP; Homsi J
Case Rep Oncol Med; 2017; 2017():8241624. PubMed ID: 29181212
[TBL] [Abstract][Full Text] [Related]
11. The role of MEK inhibitors in the treatment of metastatic melanoma.
Grimaldi AM; Simeone E; Ascierto PA
Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
[TBL] [Abstract][Full Text] [Related]
12. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
13. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
14. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
15. Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
Serra F; Barruscotti S; Dominioni T; Zuccarini A; Pedrazzoli P; Chiellino S
Curr Oncol Rep; 2021 May; 23(7):84. PubMed ID: 34009481
[TBL] [Abstract][Full Text] [Related]
16. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
Kakadia S; Yarlagadda N; Awad R; Kundranda M; Niu J; Naraev B; Mina L; Dragovich T; Gimbel M; Mahmoud F
Onco Targets Ther; 2018; 11():7095-7107. PubMed ID: 30410366
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Stege H; Haist M; Schultheis M; Fleischer MI; Mohr P; Meier F; Schadendorf D; Ugurel S; Livingstone E; Zimmer L; Herbst R; Pföhler C; Kähler K; Weichenthal M; Terheyden P; Nashan D; Debus D; Kaatz M; Ziller F; Haferkamp S; Forschner A; Leiter U; Kreuter A; Ulrich J; Kleemann J; Bradfisch F; Grabbe S; Loquai C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065877
[TBL] [Abstract][Full Text] [Related]
19. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
[TBL] [Abstract][Full Text] [Related]
20. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
